The National Institute for Health and Clinical Excellence has terminated a review of Amgen’s osteoporosis drug Prolia for National Health Service prostate cancer patients on a lack of evidence.
The Institute said it is unable to recommend Prolia (denosumab) for the treatment of therapy-induced bone loss in patients with non-metastatic prostate cancer on the NHS because it did not receive any evidence from Amgen regarding the drug’s clinical and cost-effectiveness in this setting.
http://www.pharmatimes.com/UKNews/article.aspx?id=18304
1 comment:
Wow, Nice post. It is very helpful for me. Thanks for sharing information.
Post a Comment